Mahidol University has introduced Chimeric antigen receptor (CAR) modified T-cell therapy to treat B-cell leukaemia, making Thailand the first in the Asean to adopt this cutting-edge technique.
Dr Banjong Mahaisawariya, president of Mahidol University, said the university’s ability to roll out a therapy currently used in the treatment of certain blood cancers was the result of a policy to promote integration between departments.
CAR therapy is among the few available options for sufferers of B-cell leukaemia which is often more resistant to chemotherapy than other forms of cancer. It is hoped that domestic development will exponentially ease the financial burden of treatment as it is expensive to import from overseas, he said.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
